eosinophilic chronic rhino sinusitis
Conditions
Interventions
mepolizumab 100mg/4 weeks for 4 months
Sponsors
International University of Welfare and Health, Narita hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients who are diagnosed as ECRS 2. patients who agree to be included in this trial by a document 3. patients who are older than 20 years old 4. patients who need surgery for his or her ECRS
Exclusion criteria
Exclusion criteria: 1. patients who do not agree to be included in this trial 2. patients who have had mepolizumab therapy for his or her ECRS 3. patients who are not able to obtain his or her blood or surgical samples
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| identification of genes which are highly expressed in ECRS | — |
Secondary
| Measure | Time frame |
|---|---|
| identification of molecular pathways which are involved in the mechanisms of ECRS | — |
Countries
Japan
Contacts
Public ContactKoichi Hirose
International University of Welfare and Health, Narita hospital Department of Allergy and Rheumatology
Outcome results
None listed